Original Research
Published on 13 Dec 2021
PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China
in Thoracic Oncology
![PD-L1 Test-Based Strategy With Nivolumab as the Second-Line Treatment in Advanced NSCLC: A Cost-Effectiveness Analysis in China](https://www.frontiersin.org/files/myhome article library/745493/745493_Thumb_400.jpg)
- 3,054 views
- 3 citations
Original Research
Published on 13 Dec 2021
in Thoracic Oncology
Original Research
Published on 13 Dec 2021
in Thoracic Oncology
Original Research
Published on 10 Dec 2021
in Thoracic Oncology
Original Research
Published on 10 Dec 2021
in Thoracic Oncology
Original Research
Published on 09 Dec 2021
in Thoracic Oncology
Original Research
Published on 09 Dec 2021
in Thoracic Oncology
Original Research
Published on 09 Dec 2021
in Thoracic Oncology
Original Research
Published on 08 Dec 2021
in Thoracic Oncology
Original Research
Published on 07 Dec 2021
in Thoracic Oncology
Review
Published on 01 Dec 2021
in Thoracic Oncology
Original Research
Published on 01 Dec 2021
in Thoracic Oncology
Original Research
Published on 30 Nov 2021
in Thoracic Oncology
Original Research
Published on 30 Nov 2021
in Thoracic Oncology
Original Research
Published on 26 Nov 2021
in Thoracic Oncology
Review
Published on 25 Nov 2021
in Thoracic Oncology
Editorial
Published on 23 Nov 2021
in Thoracic Oncology